These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 8498825)

  • 1. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
    Smith ME; Stone LA; Albert PS; Frank JA; Martin R; Armstrong M; Maloni H; McFarlin DE; McFarland HF
    Ann Neurol; 1993 May; 33(5):480-9. PubMed ID: 8498825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
    Barkhof F; Scheltens P; Frequin ST; Nauta JJ; Tas MW; Valk J; Hommes OR
    AJR Am J Roentgenol; 1992 Nov; 159(5):1041-7. PubMed ID: 1414773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.
    Harris JO; Frank JA; Patronas N; McFarlin DE; McFarland HF
    Ann Neurol; 1991 May; 29(5):548-55. PubMed ID: 1859184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging in multiple sclerosis: an overview.
    Colosimo M; Amatruda A; Cioffi RP
    Ital J Neurol Sci; 1992 Dec; 13(9 Suppl 14):113-23. PubMed ID: 1345732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.
    McFarland HF; Frank JA; Albert PS; Smith ME; Martin R; Harris JO; Patronas N; Maloni H; McFarlin DE
    Ann Neurol; 1992 Dec; 32(6):758-66. PubMed ID: 1471866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR Gd-DTPA enhancement of radiation brain injury.
    Nishimura R; Takahashi M; Morishita S; Sumi M; Uozumi H; Sakamoto Y
    Radiat Med; 1992; 10(3):109-16. PubMed ID: 1509102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical usefulness of MRI in acute phase of spinal multiple sclerosis--influence of high-dose steroid therapy in acute phase].
    Nomura M; Suzumura A; Anno H; Miyata E; Koga S; Yamamoto H
    Rinsho Shinkeigaku; 1995 Mar; 35(3):225-30. PubMed ID: 7614741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
    Gonzalez-Scarano F; Grossman RI; Galetta S; Atlas SW; Silberberg DH
    Ann Neurol; 1987 Mar; 21(3):300-6. PubMed ID: 3606036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
    Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
    J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis.
    Bellmann-Strobl J; Wuerfel J; Aktas O; Dörr J; Wernecke KD; Zipp F; Paul F
    Neurology; 2009 Nov; 73(20):1624-7. PubMed ID: 19917984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
    BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine.
    Taschner CA; Kirsch EC; Scheffler K; Wetzel SG; Schulte-Mönting J; Kappos L; Radü EW
    Magn Reson Imaging; 2005 Apr; 23(3):469-74. PubMed ID: 15862648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.
    Molyneux PD; Filippi M; Barkhof F; Gasperini C; Yousry TA; Truyen L; Lai HM; Rocca MA; Moseley IF; Miller DH
    Ann Neurol; 1998 Mar; 43(3):332-9. PubMed ID: 9506550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis.
    Katz D; Taubenberger JK; Cannella B; McFarlin DE; Raine CS; McFarland HF
    Ann Neurol; 1993 Nov; 34(5):661-9. PubMed ID: 8239560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis.
    Tortorella C; Bellacosa A; Paolicelli D; Fuiani A; Di Monte E; Simone IL; Giaquinto P; Livrea P; Trojano M
    J Neurol Sci; 2005 Dec; 239(1):95-9. PubMed ID: 16209877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major differences in the dynamics of primary and secondary progressive multiple sclerosis.
    Thompson AJ; Kermode AG; Wicks D; MacManus DG; Kendall BE; Kingsley DP; McDonald WI
    Ann Neurol; 1991 Jan; 29(1):53-62. PubMed ID: 1996879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
    Braun J; Baraliakos X; Golder W; Brandt J; Rudwaleit M; Listing J; Bollow M; Sieper J; Van Der Heijde D
    Arthritis Rheum; 2003 Apr; 48(4):1126-36. PubMed ID: 12687557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.
    Martinelli V; Rocca MA; Annovazzi P; Pulizzi A; Rodegher M; Martinelli Boneschi F; Scotti R; Falini A; Sormani MP; Comi G; Filippi M
    Neurology; 2009 Dec; 73(22):1842-8. PubMed ID: 19949030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.